Millipore expands into Europe with acquisition of BioAnaLab
Millipore Corporation has purchased BioAnaLab, based in Oxford, UK, which specialises in the analysis of biologic drugs and vaccines. BioAnaLab, spun out of the University of Oxford in 2002, will add cGMP support testing capabilities to Millipore’s portfolio.
US-based Millipore, a provider of equipment and services to the life sciences industry, says the acquisition will help it expand its business into Europe and strengthen its position as an outsource partner to the biopharmaceutical industry.
BioAnaLab offers assay transfer/development, validation and sample analysis, pharmacokinetics/toxicokinetics, immunogenicity, biological potency and vaccine services.
Geoff Hale, founder and ceo of BioAnaLab, will remain with Millipore and become director of biopharma services in Europe. He will work closely with Ron Bowsher, Millipore’s chief scientist for biopharma services in the US.
‘Our acquisition of BioAnaLab will allow us to build on our reputation as a trusted outsource partner in North America by establishing a presence in the fast-growing European biotech market,’ said Jonathan DiVincenzo, president of Millipore’s Bioscience Division.
Millipore says it will use its expertise in biomarker analytical services to strengthen BioAnaLab’s current offering in that area.
BioAnaLab’s facility in Oxford will complement Millipore’s plant for large molecule bioanalytical services, based in St Charles, Missouri. www.millipore.com www.bioanalab.com